A CCCG-HB-2016 regimen in the treatment of hepatoblastoma in children
10.3760/cma.j.cn113855-20200615-00480
- VernacularTitle:多学科单中心CCCG-HB-2016方案治疗儿童肝母细胞瘤疗效分析
- Author:
Wenfang TANG
;
Yi QING
;
Xianbo SHEN
;
Xiangling HE
;
Huaiyin HUANG
;
Chengguang ZHU
;
Keke CHEN
;
Xin TIAN
;
Runying ZOU
;
Chuang PENG
;
Zhihong CHEN
;
Zhiqun MAO
;
Kang ZHAO
- From:
Chinese Journal of General Surgery
2021;36(5):332-336
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the clinical efficacy of multi-disciplinary single center's CCCG-HB-2016 regimen in the treatment of hepatoblastoma (HB) in children.Methods:Clinical data of 36 HB patients treated with CCCG-HB-2016 program from Aug 2016 to March 2020 were analyzed.Results:These 36 patients included 20 boys and 16 girls. The serum AFP was all higher than 2 792 ng/ml,there was a correlation between AFP and tumor risk stratification ( H=14.973, P<0.05). Twenty eight cases (77.78%) were epithelial type and 8 cases (22.22%) were mixed epithelial mesenchymal type.All children were treated by tumor resection combined with chemotherapy, and there was a correlation between tumor risk stratification and surgical resection of liver lobe ( H=8.847, P<0.05). The probability of bone marrow suppression in the low-risk group was 58.33% (35/60),that in the intermediate-risk group was 73.49% (61/83) and in the high-risk group was 80.23% (69/86).All 36 cases were followed up to March 31, 2020,with an average follow-up of 21.9 months and the median survival was 22.5 months.The overall survival rate (OS) and event-free survival rate (EFS) were 97.2% and 83.3% respectively. Conclusions:The multidisciplinary CCCG-HB-2016 regimen was with a high success rate and along with a high incidence of bone marrow suppression.
